02325.HK
Yunkang Group Limited
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 0.47
−4.12%Year over year
Reported trailing growth
- Revenue
- -16.2%
- EBITDA
- +119.1%
- EBIT
- +112.6%
- EPS
- +108.2%
- Free cash flow
- -100.0%
- Operating cash flow
- -100.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -45.7%
- EBITDA
- -40.1%
- EBIT
- -58.4%
- Net income
- -80.2%
- EPS
- -80.4%
- Free cash flow
- -4.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026